Home › Leucemia mieloide acuta › Pennsylvania
Studi clinici su Leucemia mieloide acuta nello stato di Pennsylvania
45 studi su Leucemia mieloide acuta cercano partecipanti presso sedi nello stato di Pennsylvania.
Città nello stato di Pennsylvania
- Philadelphia34 studi
- Pittsburgh18 studi
- Harrisburg8 studi
- Allentown8 studi
- Scranton6 studi
- Reading5 studi
Testo ufficiale dello studio (inglese)
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Thomas Jefferson University Hospital, Philadelphia
In reclutamentoFase 2
Età 60 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07437950Assessment of Geriatric Evaluations Impact on New AML Guidance
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
In reclutamentoStudio osservazionale
Età 50 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05909501Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- e altri 7
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoStudio osservazionale
Età da 0 a 38 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06131801Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- e altri 4
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- e altri 6
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
In reclutamentoFase 1
Fino a 21 anni · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- e altri 4
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Geisinger Medical Center, Danville
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- e altri 6
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e altri 3
In reclutamentoFase 3
6 Months – 21 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
In reclutamentoFase 1/2
30 Days · Tutti i sessi · Aggiornato il 16 set 2026 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Spoknwrd Clinical Trials Inc., Easton
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06824168A Study of BGB-11417 in Participants With Myeloid Malignancies
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT04771130Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- UPENN Perelman Center for Advanced Medicine, Philadelphia
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06846606Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Geisinger Medical Center, Danville
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
In reclutamentoFase 3
Età da 1 a 25 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07022678A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Cancer Care Associates of York, York
In reclutamentoStudio osservazionale
Età 0 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT07154823Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Pittsburgh PA-PITT, Pittsburgh
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Pittsburgh PA-PITT, Pittsburgh
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07223814The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- e altri 3
In reclutamentoFase 1/2
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 3
29 Days – 21 Years · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Pennsylvania, Philadelphia
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT07007312Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
- UMPC Hillman Cancer Center, Pittsburgh
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07565220Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- UPMC Hillman Cancer Center, Pittsburgh
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06529731L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
In reclutamentoFase 2/3
Età da 18 a 80 · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06788756Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 1
Età da 1 a 30 · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT06177067Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Penn Medicine Abramson Cancer Center, Philadelphia
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 lug 2026 · NCT05442216CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 lug 2026 · NCT05945849CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
In reclutamento
Fino a 25 anni · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT03810196CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
In reclutamentoFase 1
Età da 0 a 29 · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT07464951A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- e altri 3
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT04068597SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 mag 2026 · NCT06222580Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Pennsylvania State University Hershey Medical Center, Hershey
In reclutamentoFase 1
Fino a 21 anni · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT05101551Massage Impact on Sleep in Pediatric Oncology
- Children's Hospital of Philadelphia, Philadelphia
In reclutamento
Età da 12 a 21 · Tutti i sessi · Aggiornato il 15 apr 2026 · NCT06892158A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- Allegheny Health Network, Pittsburgh
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555Phase IB/II of CPX-351 for Relapse Prevention in AML
- University of Pennsylvania, Philadelphia
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 mar 2026 · NCT04990102A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Thomas Jefferson University Hospital, Philadelphia
In reclutamentoFase 1
Età 12 e oltre · Tutti i sessi · Aggiornato il 16 mar 2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hospital of the University of Pennsylvania, Philadelphia
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mar 2026 · NCT05735184Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.